公开(公告)号：US20240182433A1

公开(公告)日：2024-06-06

申请号：US18414958

申请日：2024-01-17

申请人： Curis, Inc.

发明人： Shu Yu

IPC分类号： C07D271/06

CPC分类号： C07D271/06 ,  C07B2200/13

摘要： The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, including an anhydrous crystalline form, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.

公开(公告)号：US11939306B2

公开(公告)日：2024-03-26

申请号：US18101387

申请日：2023-01-25

申请人： Curis, Inc.

发明人： Shu Yu

IPC分类号： C07D271/06

CPC分类号： C07D271/06 ,  C07B2200/13

摘要： The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, including an anhydrous crystalline form, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.

公开(公告)号：US20230414582A1

公开(公告)日：2023-12-28

申请号：US18037697

申请日：2021-11-17

申请人： Curis, Inc.

发明人： Reinhard von Roemeling ,  Andrey Ugolkov ,  Robert Martell

IPC分类号： A61K31/437 ,  A61K31/519 ,  G01N33/68 ,  A61K31/4725 ,  A61K31/4439 ,  A61K31/5383 ,  A61K31/4985 ,  A61K31/573 ,  A61P35/02 ,  A61K31/4184 ,  A61K31/69

CPC分类号： A61K31/437 ,  A61K31/519 ,  G01N33/68 ,  A61K31/4725 ,  A61K31/4439 ,  A61K31/5383 ,  A61K31/4985 ,  A61K31/573 ,  A61P35/02 ,  A61K31/4184 ,  A61K31/69 ,  G01N2440/14 ,  G01N2800/52

摘要： The present disclosure relates to methods of treating certain diseases and disorders (e.g., IRAK4-associated diseases and disorders).

公开(公告)号：US20230192687A1

公开(公告)日：2023-06-22

申请号：US18081966

申请日：2022-12-15

申请人： Curis, Inc.

发明人： Xiong Cai ,  Changgeng Qian ,  Haixiao Zhai

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4545

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  Y02A50/30

摘要： The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

公开(公告)号：US11654136B2

公开(公告)日：2023-05-23

申请号：US17470410

申请日：2021-09-09

申请人： Curis, Inc.

发明人： Xiong Cai ,  Haixiao Zhai ,  Chengjung Lai ,  Changgeng Qian ,  Rudi Bao

IPC分类号： A61K31/4365 ,  C07D495/04 ,  A61K31/166 ,  C07D213/30 ,  C07D241/10

CPC分类号： A61K31/4365 ,  A61K31/166 ,  C07D213/30 ,  C07D241/10 ,  C07D495/04

摘要： The invention provides a compound of Formula I,




Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

公开(公告)号：US11560377B2

公开(公告)日：2023-01-24

申请号：US17083964

申请日：2020-10-29

申请人： Curis, Inc.

发明人： Xiong Cai ,  Changgeng Qian ,  Haixiao Zhai

IPC分类号： A61K31/4353 ,  A61K31/437 ,  C07D471/04 ,  A61K31/4545

摘要： The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

公开(公告)号：US20220249502A1

公开(公告)日：2022-08-11

申请号：US17557567

申请日：2021-12-21

申请人： Curis, Inc.

发明人： Jing Wang ,  Troy David Patterson ,  Ze Tian

IPC分类号： A61K31/5377 ,  A61K9/48 ,  A61K9/20 ,  C07K16/28

摘要： The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.

公开(公告)号：US20220168284A1

公开(公告)日：2022-06-02

申请号：US17470410

申请日：2021-09-09

申请人： Curis, Inc.

发明人： Xiong Cai ,  Haixiao Zhai ,  Chengjung Lai ,  Changgeng Qian ,  Rudi Bao

IPC分类号： A61K31/4365 ,  C07D495/04 ,  A61K31/166 ,  C07D213/30 ,  C07D241/10

摘要： The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

公开(公告)号：US20200247766A1

公开(公告)日：2020-08-06

申请号：US16651830

申请日：2018-09-27

申请人： Curis, Inc.

发明人： Shu Yu

IPC分类号： C07D271/06

摘要： The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, including an anhydrous crystalline form, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.

公开(公告)号：US20200215039A1

公开(公告)日：2020-07-09

申请号：US16736081

申请日：2020-01-07

申请人： Curis, Inc.

发明人： Xiong Cai ,  Haixiao Zhai ,  Chengjung Lai ,  Changgeng Qian ,  Rudi Bao

IPC分类号： A61K31/4365 ,  C07D241/10 ,  C07D213/30 ,  A61K31/166 ,  C07D495/04

摘要： The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.